I agree a bit disappointing with the on-going delays, pandemic has hit hard on all fronts and PIQ is not the only one impacted. The positive I took away from the report was Endo was still on track for preliminary readout this quarter.
$4.5M in bank, burn is still low thanks to revenue stream from analytics - I think we will be OK this CY. Euroz and Candour have 2.2M+ options expiring in November with a 75c strike. Endo and PromarkerD (hopefully) should be well ahead by then so that could play out to be am extra $1.6M in the bank.
These supply line issues for the reagents will be the immediate focus.
Only 2months until top line Endo results, I think it's worth the wait. Will be a significant milestone for the company and further de-risk the long term vision here.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)